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Purpose: Recent real-world studies have demonstrated that asthma control remains suboptimal 
in many patients. The aim of this study was to evaluate physicians’ perceptions of the effective-
ness of combination therapy with an inhaled corticosteroid (ICS) and a long-acting β
2
-agonist 
(LABA) in routine clinical practice.
Methods: In November 2009, UK respiratory specialists were invited by medeConnect 
Healthcare Insight to complete a survey on the effectiveness of different single- or dual-inhaler 
combinations of an ICS and a LABA in the context of asthma management. Respondents were 
permitted to specify combinations of available ICSs and LABAs, based on their knowledge 
and experience of the individual components. Questions elicited both unprompted free-text 
responses and prompted responses selected from a list of options.
Results: A total of 98 physicians completed the survey, of whom 82 (84%) gave permission 
to publish their data. The majority of respondents (63%) were consultants and 57% reported a 
caseload of more than 40 patients with asthma or chronic obstructive pulmonary disease per 
month. Fluticasone and formoterol were considered to be the most effective combination for 
the treatment of asthma (37% unprompted, 41% prompted), followed by budesonide and for-
moterol (22% unprompted, 24% prompted). The most common reasons for choosing specific 
combinations were: rapid onset of action (60%), high potency of the ICS (39%), efficacy (15%), 
experience of prescribing (13%), clinical evidence (12%), and long-lasting effect (10%). Key 
properties of the preferred fluticasone and formoterol combination were rapid onset of action 
and high potency of the ICS (79% for both).
Conclusion: The results of this survey suggest that the ICS and LABA combination considered 
most effective by UK physicians in the management of asthma is fluticasone and formoterol, 
which is not currently available as a single-inhaler combination. The development of new single-
inhaler combinations of ICSs and LABAs may improve real-world asthma management.
Keywords: asthma, LABA, ICS, combination, effectiveness, real-world
Introduction
Inhaled corticosteroids (ICSs) are the cornerstone of asthma management. National 
and international guidelines recommend combination therapy with an ICS and a long-
acting β
2
-agonist (LABA) as the first step-up option for adults and children aged 5 years 
and over whose asthma is not controlled by low-dose ICS monotherapy.1−3 Data from 
robust clinical trials have shown that currently available ICS and LABA  combinations 
are effective in the management of asthma;4−9 however, recent real-world studies have 
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demonstrated that asthma control often remains suboptimal 
in terms of both acute symptom relief and reduction in 
the risk of future exacerbations10,11 even in those receiving 
treatment,12,13 and this may not be immediately apparent to 
physicians and patients.
It is unclear whether or not the ICS and LABA com-
binations that show similar efficacy in clinical trials have 
equivalent effectiveness in real-world practice. This 
study set out to evaluate physician perceptions of the 
effectiveness of combinations of currently available ICSs 
and LABAs for the management of asthma in routine 
clinical practice.
Methods
In November 2009, UK respiratory specialists (defined as 
hospital specialists with a minimum of 5 years’ experience 
who were seeing at least 20 patients with asthma or chronic 
obstructive pulmonary disease [COPD] per month) were 
invited to complete an online survey on the effectiveness of 
different combinations of an ICS and a LABA.  Physicians 
were recruited by medeConnect Healthcare Insight via 
 Doctors.net.uk, the largest online network of medical pro-
fessionals in the UK.
In the context of a questionnaire about the manage-
ment of asthma, respondents were asked a series of 
questions to establish which single-inhaler (fixed) or dual-
inhaler (free) combination of an ICS and a LABA they con-
sidered to be the most effective treatment (see Supplementary 
information). Each question was asked twice: the first time 
(unprompted), the respondent provided free-text responses 
to open-ended questions, and the second time (prompted), 
the respondent selected their response to a closed question 
from a list of options. Unprompted (recall) questions avoid 
priming of responses through free-text answers, but may 
have limitations of under-reporting because of respondents’ 
memory; surveys using prompted (recognition) questions 
tend to find higher levels of knowledge than those using an 
unprompted format but risk seeding answers in respond-
ents’ minds.14,15 For the unprompted response, any text 
could be entered. For the prompted responses, participants 
could choose between the following single-inhaler or dual-
inhaler combinations of an ICS and a LABA: fluticasone 
and formoterol, fluticasone and salmeterol, budesonide and 
formoterol, budesonide and salmeterol, beclometasone and 
formoterol, and beclometasone and salmeterol. There was 
also the option of “Other”, to allow participants to specify 
any unlisted combination that they believed was likely to 
be the most effective. Respondents were permitted to state 
available and hypothetical single-inhaler or dual-inhaler 
combinations, based on their knowledge and experience of 
the individual components.
Before analysis, unprompted responses were grouped 
either by generic drug name (for answers about the most 
effective ICS and LABA combination) or by theme (for 
answers regarding the reasons for a particular choice). 
Representativeness was assessed in relation to National 
Health Service Workforce data on medical and dental staff 
by specialty and grade in 2009 in England16 and Wales.17 
Detailed information on workforce characteristics was only 
available for England.
Results
Demographic and clinical characteristics
Of the 98 respondents, 82 (84%) gave permission for their 
data to be included in the analysis, all of whom answered 
both the unprompted and prompted questions. Almost three-
quarters of the participants (73%) were aged 31–40 years. 
Most (63%) were consultants and the majority (57%) reported 
having a caseload of more than 40 patients with asthma or 
COPD per month (see Table 1).
Overall, 83% of respondents were from England, 9% from 
Scotland, 6% from Northern Ireland, and 2% from Wales. 
Job grade, sex, and geographical distribution of English 
respondents were similar to those of all consultants, asso-
ciate specialists, staff grades, and registrars in respir atory 
medicine in England, although specialist registrars, and 
staff in the Yorkshire and Humber region, were slightly over-
represented (Table 1). Of all consultants, associate specia-
lists, staff grades and registrars in respiratory medicine, we 
surveyed approximately 5% (68/1358) in England and 3% 
(2/59) in Wales.
Most effective iCS and LABA 
combinations
Respondents considered that the most effective combinations 
(irrespective of their current availability as single-inhaler 
or dual-inhaler combinations) would be fluticasone and 
formoterol (37% unprompted, 41% prompted), followed 
by budesonide and formoterol (22% unprompted, 24% 
prompted) (Figure 1).
When analyzing the components individually, the ICS 
considered to be most effective was fluticasone (44% 
unprompted, 49% prompted), followed by budesonide 
(22% unprompted, 26% prompted), and beclometa-
sone (17% unprompted, 22% prompted) (Figure 2A). 
The most effective LABA was thought to be formoterol 
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(84% unprompted, 87% prompted), followed by salmeterol 
(11% unprompted, 12% prompted) (Figure 2B).
Reasons for iCS and LABA choice
The most common reasons that respondents gave for choosing 
the ICS and LABA combination they considered to be most 
effective were: rapid onset of action (60%), high potency of 
the ICS (39%), efficacy (15%), experience of prescribing 
(13%), clinical evidence (12%), and long-lasting effect (10%) 
(Figure 3A). The most common reasons given for selecting 
fluticasone and formoterol (the combination most often rated 
as being most effective) were rapid onset of action (79%) 
and high potency of the ICS (79%) (Figure 3B).
Discussion
This study aimed to gain an insight into the opinions of 
UK physicians regarding the effectiveness of different 
single-inhaler or dual-inhaler combinations of an ICS and a 
LABA for the treatment of asthma. Using both unprompted 
and prompted questions,14,15 this survey revealed that the 
Table 1 Demographic and clinical characteristics of respondents
Characteristic Study population  
(UK)a  
(n = 82)
Study population  
(England)a  
(n = 68)
Source population 
(England)b  
(n = 1241)
n (%) n (%) n (%)
Sex
 Male 59 (72) 46 (68) 879 (65)
 Female 23 (28) 22 (32) 479 (35)
Age
 31–40 years 60 (73) 49 (72) nR nR
 41–50 years 17 (21) 15 (22)
  .51 years 5 (6) 4 (5)
Job grade
 Consultant 52 (63) 42 (62) 645 (47)
 Associate specialist 1 (1) 1 (1) 11 (1)
 Staff grade 1 (1) 1 (1) 10 (1)
 Specialist registrar 28 (34) 24 (35) 692 (51)
Year of qualification
 1965–1989 11 (13) 9 (7) nR nR
 1990–1994 21 (26) 19 (28)
 1995–1999 34 (41) 28 (41)
 2000–2005 16 (20) 12 (18)
number of patients with asthma/COPD seen per month
 20–40 35 (43) 21 (31) nR nR
 41–60 16 (20) 5 (7)
 61–80 7 (9) 4 (6)
 81–100 17 (21) 8 (12)
  .100 7 (9) 4 (6)
Location of current practice
 north-West 11 (13) 11 (16) 218 (16)
 north-East 5 (6) 5 (7) 92 (7)
 Yorkshire and Humber 4 (5) 4 (6) 186 (14)
 East Midlands 5 (6) 5 (7) 93 (7)
 West Midlands 6 (7) 6 (9) 160 (12)
 East of England 6 (7) 6 (9) 113 (8)
 London 15 (18) 15 (22) 267 (20)
 South-East coast 2 (2) 2 (3) 42 (3)
 South Central 6 (7) 6 (9) 75 (6)
 South-West 8 (10) 8 (12) 112 (8)
 Scotland 7 (9) nR nR
 Wales 2 (2) nR nR
 northern ireland 5 (6) nR nR
Notes: aHospital specialists with at least 5 years’ experience; bnHS Workforce data (2009) on all consultants, associate specialists, staff grade, or registrars in respiratory 
medicine in England.16
Abbreviations: COPD, chronic obstructive pulmonary disease; nHS, national Health Service; nR, not reported.
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8060
Respondents (%)
40200
Other
Mometasone
Ciclesonide
Beclometasone
Budesonide
Fluticasone
100
Prompted UnpromptedA
8060
Respondents (%)
40200
Other
100
Salmeterol
Formoterol
Prompted UnpromptedB
Figure 2 Choice of most effective (A) iCS and (B) LABA components (n = 82).
Abbreviations: iCS, inhaled corticosteroid; LABA, long-acting β2-agonist.
4540353025
Prompted
Respondents (%)
Unprompted
20151050
Other/unsure
Ciclesonide and salmeterol
Budesonide and salmeterol
Beclometasone and salmeterol
Ciclesonide and formoterol
Fluticasone and salmeterol
Beclometasone and formoterol
Budesonide and formoterol
Fluticasone and formoterol
Figure 1 Choice of most effective iCS and LABA combination (n = 82).
Abbreviations: iCS, inhaled corticosteroid; LABA, long-acting β2-agonist.
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 preferred choice of UK-based respiratory specialists to 
optimize combination therapy (ICS and a LABA) was 
fluticasone and formoterol, which is currently not available 
as a single-inhaler combination. This choice was followed 
by budesonide and formoterol, then beclometasone and 
formoterol. Our study also suggested that the most impor-
tant properties of a single- or dual-inhaler combination of 
an ICS and a LABA are high potency of the ICS and rapid 
onset of action.
The rating of fluticasone as the most effective ICS in 
combination therapies for asthma appears to be related to 
its well-established pharmacological potency. Clinical data 
show that treatment with fluticasone results in improvements 
in symptoms and lung function, and reduces the frequency 
of rescue medication use in adults and children with mild to 
severe asthma when administered at half the equivalent daily 
dose of budesonide or beclometasone.18−20
The rating of formoterol as the most effective LABA 
probably reflects its rapid onset of action compared with 
salmeterol.21,22 Furthermore, a recent systematic review 
identi fied a greater improvement in symptoms (reduced 
frequency of rescue medication use and more symptom-free 
days) and in lung function in patients treated with formoterol 
compared with those treated with salmeterol.19
This study has several strengths and limitations. 
Although the use of an online survey may have led to 
response bias, survey participants were broadly represen-
tative of the target population of respiratory consultants 
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Well tolerated
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Fewer side effects
Adjustable dosing
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Good/best LABA
Long lasting
Evidence
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Effective
Good/potent steroid
Rapid onset
A
8060
Respondents (%)
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B
Figure 3 Reasons for choice of most effective iCS and LABA components (A) overall (n = 82) and (B) for fluticasone and formoterol (n = 34).
Abbreviations: iCS, inhaled corticosteroid; LABA, long-acting β2-agonist.
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and specialist registrars, in terms of sex and geographical 
distribution. Participants were asked to give unprompted 
responses first, and these were consistent with the prompted 
responses that followed. The fact that some available ICSs 
and LABAs (eg, ciclesonide and indacaterol [not available 
in the UK at the time of the survey]) were not included in 
the list of prompted responses is unlikely to have influenced 
our results, because they were not mentioned unprompted 
or (with the exception of two mentions of ciclesonide) in 
the prompted “Other” category. Specific limitations include 
data collection from respiratory specialists, rather than 
from primary care where the majority of asthma manage-
ment takes place, and by focusing on efficacy, this study 
did not specifically address the question of safety for ICSs 
and LABAs. Also, this observational survey was a study of 
“theoretical preference”, and was not designed to capture 
current prescribing patterns, medication usage, or dosage 
modifications of current formulations. To do this, a prescrib-
ing database would be required.
Finally, data from this study are UK specific and may 
not be representative of the attitudes of respiratory special-
ists within the wider community in Europe. However, the 
results are consistent with a recent pan-European study of 
ICS-prescribing trends, in which fluticasone was shown to be 
the most widely prescribed ICS (included in 38% of inhalers 
prescribed), followed by budesonide and beclometasone.23 
Further similar research would be useful to evaluate phys-
ician perceptions of the effectiveness of combinations of 
currently available ICSs and LABAs for the management 
of other respiratory diseases, especially COPD, both in the 
specialist setting and in primary care.
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Supplementary information
Respiratory questionnaire
Eligibility criteria
Position
Which of the following best describes the position that you 
hold?
•	 Internal medicine
•	 Surgeon
•	 Gastrointestinal/colorectal medicine
•	 Obstetrics
•	 Gynecology
•	 Respiratory
•	 Other
Date of qualification
Please write in the year you qualified …
___________
[MUST BE NUMERICAL BETWEEN 1965 AND 2005]
Seniority
Which of the following best describes your role?
•	 Consultant
•	 Associate specialist
•	 Staff grade
•	 Specialist registrar (year 5+)
•	 Specialist registrar (year 3–4)
•	 Specialist registrar (year 1–2)
•	 Other
Location
Where are you currently practicing?
•	 North-West SHA
•	 North-East SHA
•	 Yorkshire and Humber SHA
•	 East Midlands SHA
•	 West Midlands SHA
•	 East of England SHA
•	 London SHA
•	 South-East Coast SHA
•	 South Central SHA
•	 South-West SHA
•	 Scotland
•	 Wales
•	 Northern Ireland
•	 Retired
•	 Not working in the UK
Patient caseload
How many patients do you see regarding asthma or COPD 
in a typical month?
Please write in the number below:
___________
Asthma management
Most effective LABA and iCS combination  
(current products)
Based upon your knowledge of the individual LABA and 
ICS components, what would you consider to be the most 
effective combination (irrespective of whether it is currently 
available or not)?
Please explain clearly.
LABA iCS
Most effective LABA and iCS combination 
(hypothetically speaking)
Again based upon your knowledge of the individual 
 components (rather than current availability), which of the 
following would you say is likely to be the most effective 
LABA and ICS combination?
Please select one:
•	 Beclometasone/formoterol
•	 Beclometasone/salmeterol
•	 Budesonide/formoterol
•	 Budesonide/salmeterol
•	 Fluticasone/formoterol
•	 Fluticasone/salmeterol
•	 Other (please specify)
Reasons for most effective combination
Why do you say that ,answer at Q2. is likely to be the most 
effective LABA and ICS combination?
Please explain fully.
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